GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+21.29%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.97B
AUM Growth
+$710M
(+17%)
Cap. Flow
+$57.6M
Cap. Flow
% of AUM
1.16%
Top 10 Holdings %
Top 10 Hldgs %
43.85%
Holding
701
New
35
Increased
130
Reduced
246
Closed
41
Top Buys
| 1 |
British American Tobacco
BTI
|
$31.2M |
| 2 |
SAP
SAP
|
$28.7M |
| 3 |
Robinhood
HOOD
|
$28.4M |
| 4 |
UnitedHealth
UNH
|
$25.3M |
| 5 |
Celestica
CLS
|
$20.1M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$36.5M |
| 2 |
TSMC
TSM
|
$32.1M |
| 3 |
Meta Platforms (Facebook)
META
|
$28.1M |
| 4 |
KE Holdings
BEKE
|
$20.4M |
| 5 |
Trip.com Group
TCOM
|
$16.6M |
Sector Composition
| 1 | Technology | 46.23% |
| 2 | Consumer Discretionary | 14.24% |
| 3 | Communication Services | 13.85% |
| 4 | Consumer Staples | 7.1% |
| 5 | Healthcare | 7.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Cousins Properties
CUZ
$4.95B
| $88.9K | ﹤0.01% |
2,962
-213
| -7% | -$6.4K |
|
377
Kite Realty
KRG
$5.11B
| $87.8K | ﹤0.01% |
3,877
-284
| -7% | -$6.43K |
|
378
Avidity Biosciences
RNA
$6.48B
| $86.8K | ﹤0.01% |
3,055
| – | – |
|
379
Ultragenyx Pharmaceutical
RARE
$3.07B
| $86K | ﹤0.01% |
2,364
| – | – |
|
380
Scholar Rock
SRRK
$3.02B
| $84.9K | ﹤0.01% |
2,396
| – | – |
|
381
Protagonist Therapeutics
PTGX
$3.77B
| $84.3K | ﹤0.01% |
1,526
| – | – |
|
382
Americold
COLD
$3.98B
| $79.3K | ﹤0.01% |
4,771
-344
| -7% | -$5.72K |
|
383
Berkshire Hathaway Class B
BRK.B
$1.08T
| $78.7K | ﹤0.01% |
162
-1,385
| -90% | -$673K |
|
384
EPR Properties
EPR
$4.05B
| $78.2K | ﹤0.01% |
1,342
-92
| -6% | -$5.36K |
|
385
Phillips Edison & Co
PECO
$4.54B
| $77.6K | ﹤0.01% |
2,215
-107
| -5% | -$3.75K |
|
386
SL Green Realty
SLG
$4.4B
| $77.5K | ﹤0.01% |
1,252
-107
| -8% | -$6.62K |
|
387
Sabra Healthcare REIT
SBRA
$4.56B
| $77.4K | ﹤0.01% |
4,196
-285
| -6% | -$5.26K |
|
388
Legend Biotech
LEGN
$6.66B
| $74.2K | ﹤0.01% |
2,092
| – | – |
|
389
Kymera Therapeutics
KYMR
$3.11B
| $72.4K | ﹤0.01% |
1,658
| – | – |
|
390
Macerich
MAC
$4.74B
| $72.1K | ﹤0.01% |
4,454
-253
| -5% | -$4.09K |
|
391
Independence Realty Trust
IRT
$4.22B
| $71.9K | ﹤0.01% |
4,065
-198
| -5% | -$3.5K |
|
392
Crinetics Pharmaceuticals
CRNX
$3.35B
| $68.3K | ﹤0.01% |
2,375
| – | – |
|
393
Kilroy Realty
KRC
$5.05B
| $68K | ﹤0.01% |
1,982
-142
| -7% | -$4.87K |
|
394
Amneal Pharmaceuticals
AMRX
$3.02B
| $64.2K | ﹤0.01% |
7,934
| – | – |
|
395
Mirum Pharmaceuticals
MIRM
$3.82B
| $62.5K | ﹤0.01% |
1,228
| – | – |
|
396
Instil Bio
TIL
$213M
| $62.5K | ﹤0.01% |
+3,000
| New | +$62.5K |
|
397
Alvotech
ALVO
$2.6B
| $62.3K | ﹤0.01% |
6,832
| – | – |
|
|
MRP
398
Millrose Properties, Inc.
MRP
$5.68B
| $62K | ﹤0.01% |
+2,176
| New | +$62K |
|
399
Tanger
SKT
$3.94B
| $61.2K | ﹤0.01% |
2,000
-97
| -5% | -$2.97K |
|
400
Xenon Pharmaceuticals
XENE
$3.02B
| $61.1K | ﹤0.01% |
1,952
| – | – |
|